Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin Glargine Plus Insulin Glulisine MDI Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Evaluating Differences in Patient Reported Outcomes.

Trial Profile

Insulin Glargine Plus Insulin Glulisine MDI Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Evaluating Differences in Patient Reported Outcomes.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2010

At a glance

  • Drugs Insulin aspart/insulin protamine aspart; Insulin glargine; Insulin glulisine; Insulin neutral protamine lispro/insulin lispro
  • Indications Diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Jun 2010 Results have been presented at the 70th Annual Scientific Sessions of the American Diabetes Association.
    • 26 Jun 2010 Results reported in two abstracts at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA), according to a sanofi aventis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top